Baseline Clinical and Pet-Ct Tumor Burden Parameters Do Not Predict Outcome of Relapse/Refractory Aggressive B Cell Lymphoma Patients Treated With Anti-Cd19 Car T-Cells
Hematological Oncology - United Kingdom
doi 10.1002/hon.188_2631
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley